×
-0.00150537634408603 0.00860215053763453 0.0311827956989248 0.0323096774193549 0.0510279569892474 0.0860215053763441 0.0731182795698926 0.0655913978494625
Stock impact report

Revance slips 6% on Allergan takeout of Bonti [Seeking Alpha]

Revance Therapeutics, Inc (RVNC)  More Company Research Source: Seeking Alpha
Last revance therapeutics, inc earnings: 5/8 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.revance.com
PDF Revance Therapeutics ( RVNC ) is down on light volume in early trade on the heels of Allergan's announced acquisition of Bonti, a developer of fast-acting neurotoxin treatments, including a Phase 2 candidate for frown lines. Revance plans to file a U.S. application for frown line treatment daxibotulinumtoxinA in H1 2019. Previously: Allergan to acquire Bonti for $195M (Sept. 14) See all stocks on the move » Now read: Principia Biopharma Readies $75 Million IPO Plans » Subscribe for full text news in your inbox [Read more]
Impact snapshot Event time: RVNC
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
RVNC alerts
from News Quantified
Opt-in for
RVNC alerts

from News Quantified
Opt-in for
RVNC alerts

from News Quantified